Home R & D

CRAMS

The Contract Research and Manufacturing Services (CRAMS)

We have completely integrated R&D, technology and engineering capabilities that enable us to be cost effective partners on a sustainable basis. We have built strong alliances and continuing relationships with top global generic companies to offer R&D and formulation development services.

The Contract Manufacturing Division is being set up to address the challenges and opportunities created due to increasing R&D costs, low R&D productivity, impending patent expirations and at the same time, pressure to reduce healthcare costs. This in turn has propelled global pharma majors to cut costs and improve overall profitability. This is expected to translate into a strong outsourcing potential for low cost manufacturing destinations like India.

India offers the following advantages to innovator companies

• Strong chemistry skills as demonstrated in the domestic market
• Low labour cost (1/7th ) compare to that in USA
• Lower cost of manufacturing (30-40%) as compared to western countries with same quality
• Integrated business model creating a 'one stop' shop for innovators
• India has six times the number of trained chemists as the US, which are available at 1/10^th of the cost
• India has over 75 USFDA approved plants (the highest no. of FDA approved plants outside the US)
• Abundant English speaking skilled manpower
• High quality telecom and IT infrastructure
• Indian companies have better regulatory skills like IPR adherence

Why Marksans Pharma CRAMS?

• Marksans Pharma has alliances with the top MNC generic companies for contract manufacturing of 30 generic products for the European markets
• We have long-term (7-10 years) licensing agreements with several companies for development and supply of products
• Global presence
• Low cost manufacturing base
• World class manufacturing capacities/ plant, huge capacities
• Approvals from Global Health Authorities like US FDA, UK MHRA, Australia TGA
• Strong R&D and dossier development capabilities
• More than 125 plus product IP – for regulated markets
• More than 500 plus product IP’s – in semi-regulated markets
• Only company in India having USFDA/ TGA/ MHRA approval for softgel products
• Among the very few companies in India offering CRAMS for US/ global markets into formulation development and manufacturing

Strategy

• The company plans to enhance its product portfolio with the addition of 12-13 products every year
• Offering CRAMS for existing and emerging markets is envisaged as one of the major driver and revenue earner for the company